Several clinical trials with mTOR inhibitors are currently underway; i) a phase II clinical trial assessing single agent temsirolimus in ovarian, fallopian tube or primary peritoneal cancer ii) a phase I study in combination with topotecan in patients with gynaecological cancers and iii) a study of temsirolimus in patients with ovarian cancer with CA125 only relapse investigating progression-free survival. This evidence concerns the gene MTOR and ovarian carcinoma.